908 Devices poised to modernize upstream bioprocess analytics with a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
BOSTON, July 25, 2019 /PRNewswire/ -- 908 Devices Inc., a pioneer of purpose-built analytical devices for chemical and biomolecular analysis, announced it has been awarded a technical project grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). This award will fuel continued development of simple, at-line bioreactor process analytics – a collaboration between 908 Devices, MilliporeSigma, the University of North Carolina at Chapel Hill, North Carolina State University, and other leading biopharmaceutical manufacturers. The mission of NIIMBL is to accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce. In concert with that mission, this project tackles the challenge of monitoring metabolic attributes in bioreactors with just a fraction of the test complexity and sample volume of what is required by today's technology. The results will offer insight into cell growth and critical process attributes integral to biopharmaceutical development. "We're excited to be selected as a NIIMBL grant recipient and look forward to working with our partners on the development of our next-gen capabilities," said Dr. Kevin Knopp, CEO & Co-founder of 908 Devices. "Receiving this award from NIIMBL and its industry partners further validates that there are strong needs that align with our proficiencies in microfluidic separations, high-fidelity mass spectrometry, and artificial intelligence." "NIIMBL grants are key in driving much needed innovation in the biopharmaceutical manufacturing space. They also create unique partnerships between technology developers and industry leaders, resulting in commercial products that both improve bioprocesses and ultimately raise the quality of the biopharmaceuticals produced," said Dr. J. Michael Ramsey, Minnie N. Goldby Distinguished Professor of Chemistry, and Science Founder, Director, and Chair of Scientific Advisory Board at 908 Devices. 908 Devices was one of several applicants in the NIIMBL Project 2.1 Call. A projected total of $6.5 MM is expected to be awarded to grant recipients. To learn more about NIIMBL, please visit niimbl.org. About 908 Devices About NIIMBL View original content to download multimedia:http://www.prnewswire.com/news-releases/908-devices-poised-to-modernize-upstream-bioprocess-analytics-with-a-grant-from-the-national-institute-for-innovation-in-manufacturing-biopharmaceuticals-niimbl-300890741.html SOURCE 908 Devices |